文献速递间质性肺疾病

进展性纤维化间质性肺疾病的临床队列研究(PROGRESS研究)

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study).
PubMed 文献 · Eur Respir J · 2021-02-11

本研究在真实世界单中心临床队列中评估了非IPF的进展性纤维化间质性肺疾病(PF-ILD)患者的特征与结局。共筛查1395例纤维化ILD患者,168例符合进展性纤维化表型,165例可评估患者中位年龄61岁,基线平均FVC为预计值74±22%,中位随访46.2个月,3年总生存率83%、5年72%,多因素Cox回归显示死亡率与过去24个月内相对FVC下降≥10%、年龄≥50岁及诊断亚组显著相关。

要点

  • 非IPF的PF-ILD患者肺功能持续下降,年化FVC下降约136±328 mL。
  • 3年总生存率83%,5年72%,死亡率与相对FVC下降≥10%独立相关。
  • 年龄≥50岁和诊断亚组也是死亡率的独立预测因素。

核心结论

  • 在未接受抗纤维化治疗的PF-ILD患者中,疾病表现为肺功能持续下降,且该下降可预测死亡率。

研究设计与样本

  • 真实世界、单中心、回顾性临床队列研究,筛查2010-2017年连续成人纤维化ILD患者1395例。

主要发现

  • 617例为非IPF或非CPFE的ILD,其中168例具有进展性纤维化表型,165例可评估。
  • 可评估患者中位年龄61岁,57%为女性,基线平均FVC为预计值74±22%,中位随访46.2个月。
  • 第一年年度化FVC下降估计为136±328 mL(线性混合模型)。
  • 3年总生存率83%,5年总生存率72%。
  • 多因素Cox回归显示死亡率与过去24个月内相对FVC下降≥10%(p<0.05)、年龄≥50岁(p<0.01)及诊断亚组(p<0.01)显著相关。

临床怎么用

  • 对非IPF的纤维化ILD患者应识别进展性纤维化表型,监测FVC下降以评估死亡风险。

局限性

  • 研究为单中心回顾性设计,接受尼达尼布或吡非尼酮治疗的患者在生存和进展分析中被删失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In patients with chronic fibrosing interstitial lung disease (ILD), a progressive fibrosing phenotype (PF-ILD) may develop, but information on the frequency and characteristics of this population outside clinical trials is lacking.We assessed the characteristics and outcomes of patients with PF-ILD other than idiopathic pulmonary fibrosis (IPF) in a real-world, single-centre clinical cohort. The files of all consecutive adult patients with fibrosing ILD (2010-2017) were examined retrospectively for pre-defined criteria of ≥10% fibrosis on high-resolution computed tomography and progressive disease during overlapping windows of 2 years. Baseline was defined as the date disease progression was identified. Patients receiving nintedanib or pirfenidone were censored from survival and progression analyses.In total, 1395 patients were screened; 617 had ILD other than IPF or combined pulmonary fibrosis and emphysema, and 168 had progressive fibrosing phenotypes. In 165 evaluable patients, median age was 61 years; 57% were female. Baseline mean forced vital capacity (FVC) was 74±22% predicted. Median duration of follow-up was 46.2 months. Annualised FVC decline during the first year was estimated at 136±328 mL using a linear mixed model. Overall survival was 83% at 3 years and 72% at 5 years. Using multivariate Cox regression analysis, mortality was significantly associated with relative FVC decline ≥10% in the previous 24 months (p<0.05), age ≥50 years (p<0.01) and diagnosis subgroup (p<0.01).In this cohort of patients with PF-ILD not receiving antifibrotic therapy, the disease followed a course characterised by continued decline in lung function, which predicted mortality.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Nasser M, Larrieu S, Si-Mohamed S, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J. 2021. PMID: 32943410. doi:10.1183/13993003.02718-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。